These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17646352)

  • 1. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
    McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
    Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
    Gallien S; Journot V; Rozenbaum W; Yéni P; Morlat P; Poizot-Martin I; Reynes J; Reliquet V; Leclercq P; Simon F; Chêne G; Molina JM;
    J Antimicrob Chemother; 2011 Jan; 66(1):184-91. PubMed ID: 21036772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.
    Saez-Llorens X; Violari A; Ndiweni D; Yogev R; Cashat M; Wiznia A; Chittick G; Harris J; Hinkle J; Blum MR; Adda N; Rousseau F;
    Pediatrics; 2008 Apr; 121(4):e827-35. PubMed ID: 18332076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.
    Molina JM; Ferchal F; Rancinan C; Raffi F; Rozenbaum W; Sereni D; Morlat P; Journot V; Decazes JM; Chêne G
    J Infect Dis; 2000 Aug; 182(2):599-602. PubMed ID: 10915095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).
    Molina JM; Journot V; Furco A; Palmer P; De Castro N; Raffi F; Morlat P; May T; Rancinan C; Chêne G;
    Antivir Ther; 2007; 12(3):417-22. PubMed ID: 17591032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
    Maggiolo F; Migliorino M; Maserati R; Pan A; Rizzi M; Provettoni G; Rizzi L; Suter F;
    Antivir Ther; 2001 Dec; 6(4):249-53. PubMed ID: 11878406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.
    Saag MS; Cahn P; Raffi F; Wolff M; Pearce D; Molina JM; Powderly W; Shaw AL; Mondou E; Hinkle J; Borroto-Esoda K; Quinn JB; Barry DW; Rousseau F;
    JAMA; 2004 Jul; 292(2):180-9. PubMed ID: 15249567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
    Sánchez-Conde M; Palacios R; Sanz J; Rodríguez-Novoa S; Rivas P; Santos J; Sola J; Asensi V; de Mendoza C; Estrada V; Barreiro P; González-Lahoz J; Jiménez-Nacher I; Soriano V
    AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1237-41. PubMed ID: 17961110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
    Pavia-Ruz N; Rossouw M; Sáez-Llorens X; Bunupuradah T; Taylor M; Yang R; Sevinsky H; Krystal M; Lataillade M; Seekins D; Biguenet S
    Pediatr Infect Dis J; 2015 Dec; 34(12):1355-60. PubMed ID: 26379163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks.
    Jayaweera D; Dejesus E; Nguyen KL; Grimm K; Butcher D; Seekins DW
    HIV Clin Trials; 2009; 10(6):375-84. PubMed ID: 20133268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study.
    Santos J; Palacios R; López M; Gálvez MC; Lozano F; de la Torre J; Ríos MJ; López-Cortés LF; Rivero A; Torres-Tortosa M;
    HIV Clin Trials; 2005; 6(6):320-8. PubMed ID: 16566083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.